IPO ARMY

IPOs, SPACs, BIO Stocks. NOT financial advice! For all IPO and SPAC updates, please join my Patreon page:

[IPO ARMY @IPOARMY]

Who’s ready for the @SpaceX IPO?

SpaceX is aiming to file its IPO prospectus as soon as early next week, per multiple reports. Listing possible in June.
• Potential Raise: Over $75 billion — could be the largest IPO in history!
• Target Valuation: ~$1.5–1.75 trillion.

[IPO ARMY @IPOARMY]

$ALGS back on the move 6M share float /$80M MC, anchored by best-/first-in-class CHB backbone therapy advancing through mid-Phase 2b, alongside a high-value MASH program with recent GLP-1 + ALG combination data demonstrating weight loss, potential out-licensing deal in 1H ’26.

[IPO ARMY @IPOARMY]

$ALGS 👀

[IPO ARMY @IPOARMY]

One year ago $TERN was $5.50. It just hit $45.00 (+720%). That’s biotech — the gems are out there if you’re early and patient.

[IPO ARMY @IPOARMY]

I officially added $TERN to my bio portfolio. I believe they are highly undervalued with multiple drugs in thier pipeline. TERN-601 (GLP-1), TERN-501 (THR-β agonist) and TERN-701 (treating CML) with an expected update im early December.

[Bizarre 🏝️ @BizarreStocks]

$ALGS one to watch again.

This time last year ran from $7 to $46, in a month and a half. After that it was insanely oversold to ~$4 a share, now at $9.

Another example of an undervalued biotech, amazing opportunity.
Up 35.5% this week, smart money is starting to roll back in.

[IPO ARMY @IPOARMY]

$ALGS 👀

[IPO ARMY @IPOARMY]

$XBI

[IPO ARMY @IPOARMY]

$SPRB $124 bid. “It’s the float, stupid”.

[IPO ARMY @IPOARMY]

$3B valuation for MASH P3. What’s the combined valuation for $ALGS with best/first-in-class MASH + CHB? CEO says MASH deal expected early 2026. Who makes the next move — @merck @pfizer @JNJNews @GileadSciences ?

[IPO ARMY @IPOARMY]

$ETNB stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash represents total equity value of up to approximately $3.5B.

[IPO ARMY @IPOARMY]

$ETNB stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash represents total equity value of up to approximately $3.5B.

[IPO ARMY @IPOARMY]

$CLBR July 16th 🍽️

[IPO ARMY @IPOARMY]

$CLBR ⏰ 💣

[IPO ARMY @IPOARMY]

They expect to announce out licensing deal for mash drug before year end.

[IPO ARMY @IPOARMY]

$ALGS worth watching yesterday’s conference!

https://t.co/qLOccb019u

[IPO ARMY @IPOARMY]

$ALGS worth watching yesterday’s conference!

https://t.co/qLOccb019u

[IPO ARMY @IPOARMY]

@Joshthe3rd_ Unless they get a partnership for mash drug. Supposedly the plan.

[IPO ARMY @IPOARMY]

@Mr_L__1 @ClbrSpac 🥳

[IPO ARMY @IPOARMY]

$DBVT $7 -$11

[IPO ARMY @IPOARMY]

The One Allergy Stock That Might Outgrow $AQST and $SPRY Combined:
https://t.co/w1MSNWmeHR

[IPO ARMY @IPOARMY]

$CLBR

[IPO ARMY @IPOARMY]

$CLBR ⏰ 💣

[IPO ARMY @IPOARMY]

$CLBR ⏰ 💣

[IPO ARMY @IPOARMY]

$CLBR 💎🖐️

[IPO ARMY @IPOARMY]

$CLBR 💎🖐️

[IPO ARMY @IPOARMY]

$DBVT 🔥🔥

[IPO ARMY @IPOARMY]

The One Allergy Stock That Might Outgrow $AQST and $SPRY Combined:
https://t.co/w1MSNWmeHR

[IPO ARMY @IPOARMY]

$ALGS 👀

[IPO ARMY @IPOARMY]

I'll be the first to say it—Baker Brothers led the $105M private placement announced today for $ALGS.

“There are always those who know how to play the game.”

Baker Brothers have a proven track record of identifying biotech winners early, backing companies that went on
1/3